Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Purchased by JPMorgan Chase & Co.

JPMorgan Chase & Co. raised its stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 50.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 27,490 shares of the company’s stock after purchasing an additional 9,225 shares during the quarter. JPMorgan Chase & Co. owned about 0.05% of Zevra Therapeutics worth $229,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. acquired a new position in Zevra Therapeutics in the fourth quarter valued at $94,000. Virtu Financial LLC acquired a new position in shares of Zevra Therapeutics in the 3rd quarter valued at about $127,000. SG Americas Securities LLC grew its holdings in shares of Zevra Therapeutics by 54.6% during the 4th quarter. SG Americas Securities LLC now owns 23,500 shares of the company’s stock worth $196,000 after purchasing an additional 8,302 shares during the period. Corebridge Financial Inc. increased its position in Zevra Therapeutics by 16.9% during the 4th quarter. Corebridge Financial Inc. now owns 26,294 shares of the company’s stock worth $219,000 after purchasing an additional 3,801 shares in the last quarter. Finally, EntryPoint Capital LLC purchased a new position in Zevra Therapeutics in the fourth quarter valued at approximately $221,000. 35.03% of the stock is owned by hedge funds and other institutional investors.

Zevra Therapeutics Price Performance

Shares of Zevra Therapeutics stock opened at $8.00 on Friday. The firm has a market cap of $437.43 million, a P/E ratio of -4.06 and a beta of 1.94. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.88 and a current ratio of 2.88. Zevra Therapeutics, Inc. has a twelve month low of $4.20 and a twelve month high of $9.76. The firm’s 50-day simple moving average is $7.50 and its 200-day simple moving average is $8.09.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its earnings results on Tuesday, March 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.28). The company had revenue of $12.00 million for the quarter, compared to analyst estimates of $8.93 million. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. As a group, research analysts expect that Zevra Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Insiders Place Their Bets

In other Zevra Therapeutics news, EVP Joshua Schafer sold 10,500 shares of the company’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total transaction of $82,530.00. Following the completion of the sale, the executive vice president now directly owns 29,486 shares in the company, valued at $231,759.96. This represents a 26.26 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director John B. Bode acquired 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 19th. The shares were acquired at an average price of $7.96 per share, with a total value of $79,600.00. Following the completion of the transaction, the director now owns 40,000 shares in the company, valued at $318,400. The trade was a 33.33 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold 85,773 shares of company stock valued at $674,176 in the last 90 days. 2.40% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

ZVRA has been the subject of several recent research reports. Guggenheim increased their price objective on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, March 13th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $25.00 price target on shares of Zevra Therapeutics in a report on Wednesday, March 12th. Canaccord Genuity Group boosted their price objective on Zevra Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, March 13th. Citigroup reiterated an “outperform” rating on shares of Zevra Therapeutics in a report on Wednesday, March 12th. Finally, HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Zevra Therapeutics in a research report on Thursday, March 13th. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $22.29.

Zevra Therapeutics Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.